Prognostic value of tumor-infiltrating lymphocytes in estrogen receptor-positive and human epidermal growth factor receptor 2-negative breast cancer. 2021

Chikako Honda, and Sasagu Kurozumi, and Ayaka Katayama, and Bishoy Hanna-Khalil, and Kei Masuda, and Yuko Nakazawa, and Misato Ogino, and Sayaka Obayashi, and Reina Yajima, and Takaya Makiguchi, and Tetsunari Oyama, and Jun Horiguchi, and Ken Shirabe, and Takaaki Fujii
Department of General Surgical Science, Gunma University Graduate School of Medicine, Maebashi, Gunma 371-8511, Japan.

Tumor-infiltrating lymphocytes (TILs) are a significant prognostic factor in triple-negative breast cancer. However, the clinicopathological significance of TILs in estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer remains unclear. The purpose of the present study was to evaluate the role of TILs in the prognosis of ER-positive and HER2-negative breast cancer. A total of 65 consecutive patients with ER-positive and HER2-negative breast cancer were examined. TILs in stromal tissue (str-TILs) were graded using the International TILs Working Group criteria. The association between several clinicopathological factors and TIL grade were investigated, and the prognostic impact of TILs was compared between luminal A-like and luminal B-like breast cancer. A total of 51 patients (78.5%) had low-grade (0-10%), 11 (16.9%) had intermediate (10-40%) and 3 (4.6%) had high-grade (40-90%) str-TIL levels. There was a significant association between high levels of Ki67 expression and a high str-TIL count. Relapse-free survival was significantly worse in patients with luminal B-like cancer compared with that in patients with luminal A-like cancer. Patients with an intermediate or high str-TIL count had a better prognosis compared with those with a low str-TIL count. All patients with luminal B-like cancer and intermediate or high str-TIL levels developed no recurrence during follow-up. In conclusion, there was a significant correlation between high-grade str-TIL levels and high tumor cell proliferation rate, as well as high levels of Ki67 expression.

UI MeSH Term Description Entries

Related Publications

Chikako Honda, and Sasagu Kurozumi, and Ayaka Katayama, and Bishoy Hanna-Khalil, and Kei Masuda, and Yuko Nakazawa, and Misato Ogino, and Sayaka Obayashi, and Reina Yajima, and Takaya Makiguchi, and Tetsunari Oyama, and Jun Horiguchi, and Ken Shirabe, and Takaaki Fujii
February 2019, Oncology letters,
Chikako Honda, and Sasagu Kurozumi, and Ayaka Katayama, and Bishoy Hanna-Khalil, and Kei Masuda, and Yuko Nakazawa, and Misato Ogino, and Sayaka Obayashi, and Reina Yajima, and Takaya Makiguchi, and Tetsunari Oyama, and Jun Horiguchi, and Ken Shirabe, and Takaaki Fujii
August 2021, Journal of breast cancer,
Chikako Honda, and Sasagu Kurozumi, and Ayaka Katayama, and Bishoy Hanna-Khalil, and Kei Masuda, and Yuko Nakazawa, and Misato Ogino, and Sayaka Obayashi, and Reina Yajima, and Takaya Makiguchi, and Tetsunari Oyama, and Jun Horiguchi, and Ken Shirabe, and Takaaki Fujii
May 2018, Breast cancer (Tokyo, Japan),
Chikako Honda, and Sasagu Kurozumi, and Ayaka Katayama, and Bishoy Hanna-Khalil, and Kei Masuda, and Yuko Nakazawa, and Misato Ogino, and Sayaka Obayashi, and Reina Yajima, and Takaya Makiguchi, and Tetsunari Oyama, and Jun Horiguchi, and Ken Shirabe, and Takaaki Fujii
December 2015, World journal of clinical oncology,
Chikako Honda, and Sasagu Kurozumi, and Ayaka Katayama, and Bishoy Hanna-Khalil, and Kei Masuda, and Yuko Nakazawa, and Misato Ogino, and Sayaka Obayashi, and Reina Yajima, and Takaya Makiguchi, and Tetsunari Oyama, and Jun Horiguchi, and Ken Shirabe, and Takaaki Fujii
April 2024, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Chikako Honda, and Sasagu Kurozumi, and Ayaka Katayama, and Bishoy Hanna-Khalil, and Kei Masuda, and Yuko Nakazawa, and Misato Ogino, and Sayaka Obayashi, and Reina Yajima, and Takaya Makiguchi, and Tetsunari Oyama, and Jun Horiguchi, and Ken Shirabe, and Takaaki Fujii
October 2020, Gland surgery,
Chikako Honda, and Sasagu Kurozumi, and Ayaka Katayama, and Bishoy Hanna-Khalil, and Kei Masuda, and Yuko Nakazawa, and Misato Ogino, and Sayaka Obayashi, and Reina Yajima, and Takaya Makiguchi, and Tetsunari Oyama, and Jun Horiguchi, and Ken Shirabe, and Takaaki Fujii
December 2005, American journal of clinical oncology,
Chikako Honda, and Sasagu Kurozumi, and Ayaka Katayama, and Bishoy Hanna-Khalil, and Kei Masuda, and Yuko Nakazawa, and Misato Ogino, and Sayaka Obayashi, and Reina Yajima, and Takaya Makiguchi, and Tetsunari Oyama, and Jun Horiguchi, and Ken Shirabe, and Takaaki Fujii
July 2010, Zhonghua zhong liu za zhi [Chinese journal of oncology],
Chikako Honda, and Sasagu Kurozumi, and Ayaka Katayama, and Bishoy Hanna-Khalil, and Kei Masuda, and Yuko Nakazawa, and Misato Ogino, and Sayaka Obayashi, and Reina Yajima, and Takaya Makiguchi, and Tetsunari Oyama, and Jun Horiguchi, and Ken Shirabe, and Takaaki Fujii
September 2014, Breast cancer research : BCR,
Chikako Honda, and Sasagu Kurozumi, and Ayaka Katayama, and Bishoy Hanna-Khalil, and Kei Masuda, and Yuko Nakazawa, and Misato Ogino, and Sayaka Obayashi, and Reina Yajima, and Takaya Makiguchi, and Tetsunari Oyama, and Jun Horiguchi, and Ken Shirabe, and Takaaki Fujii
October 1989, Breast cancer research and treatment,
Copied contents to your clipboard!